Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links
Autore:
Vasan, S; Foiles, PG; Founds, HW;
Indirizzi:
Alteon Inc, Ramsey, NJ 07446 USA Alteon Inc Ramsey NJ USA 07446Alteon Inc, Ramsey, NJ 07446 USA
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 11, volume: 10, anno: 2001,
pagine: 1977 - 1987
SICI:
1354-3784(200111)10:11<1977:TPOAIA>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLYCATION END-PRODUCTS; INDUCED DIABETIC RATS; LOW-DENSITY-LIPOPROTEIN; ADVANCED GLYCOSYLATION; IN-VITRO; IMMUNOCHEMICAL DETECTION; LENS CRYSTALLINS; PHYSIOLOGICAL CONDITIONS; AMINOGUANIDINE PREVENTS; ALZHEIMERS-DISEASE;
Keywords:
advanced glycosylation end products; age-related diseases; cross-link breakers; ALT-711; diabetic complications; non-enzymatic glycosylation; pimagedine;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
97
Recensione:
Indirizzi per estratti:
Indirizzo: Vasan, S Alteon Inc, 170 Williams Dr, Ramsey, NJ 07446 USA Alteon Inc 170 Williams Dr Ramsey NJ USA 07446 msey, NJ 07446 USA
Citazione:
S. Vasan et al., "Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links", EXPERT OP I, 10(11), 2001, pp. 1977-1987

Abstract

Glucose and other reducing sugars react non-enzymatically with proteins leading to the formation of advanced glycosylation end products (AGEs) and AGE-derived protein cross-linking. Formation of AGEs is a normal physiological process, which is accelerated under the hyperglycaemic condition in diabetes. Under normal conditions, AGEs build up slowly and accumulate as one ages. Numerous studies have indicated that AGEs contribute to the pathological events leading to diabetic complications, such as age-related diseases, including nephropathy, retinopathy, vasculopathy and neuropathy. Potential therapeutic approaches to prevent these complications include pharmacological inhibition of AGE formation and disruption of pre-formed AGE-protein cross-links. Studies using animal models and preliminary clinical trials have shown the ability of the AGE-inhibitor, pimagedine and the cross-link breaker, ALT-711, to reduce the severity of pathologies of advanced glycosylation. These agents offer potential treatments for glucose-derived complicationsof diabetes and ageing.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 07:49:17